Ebos Group Ltd

EBO: XNZE (NZL)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|.S>LOCK|#RBdLOCK|<BFs?#S%

Ebos Group Earnings: Shares Undervalued, With Margins Poised to Expand Near-Term

Ebos' interim 2026 underlying EBITDA grew 3% to AUD 300 million. Sales rose 13%, but profitability fell on lower-margin weight-loss drugs and a margin-dilutive New Zealand acquisition. Full-year guidance was reaffirmed, implying second-half underlying EBITDA lifting to roughly AUD 325 million.

Sponsor Center